

his

(FILE 'HOME' ENTERED AT 14:00:28 ON 25 AUG 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 14:00:43 ON 25 AUG 2003

SEA KOBAYASHI, K/AU AND COLONOCYTE?

0* FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE BIOCOMMERCE
6 FILE BIOSIS
3 FILE BIOTECHNO
1 FILE CANCERLIT
1 FILE CAPLUS
0* FILE CIN
0* FILE DRUGLAUNCH
0* FILE DRUGMONOG2
0* FILE DRUGNL
0* FILE DRUGUPDATES
3 FILE EMBASE
0* FILE FOREGE
2 FILE LIFESCI
0* FILE MEDICONF
3 FILE MEDLINE
0* FILE NUTRACEUT
1 FILE PASCAL
0* FILE PCTGEN
0* FILE PHAR
0* FILE PHARMAML
0* FILE PHIC
0* FILE PHIN
0* FILE RDISCLOSURE
2 FILE SCISEARCH

L1 QUE KOBAYASHI, K/AU AND COLONOCYTE?

FILE 'BIOSIS, BIOTECHNO, EMBASE, MEDLINE, LIFESCI, SCISEARCH, CANCERLIT, CAPLUS, PASCAL' ENTERED AT 14:02:05 ON 25 AUG 2003

L2 22 S KOBAYASHI, K/AU AND COLONOCYTE?

L3 8 DUP REM L2 (14 DUPLICATES REMOVED)

L4 0 S EXPRESS AND IGG FC AND COLONOCYTES AND KOBAYASHI, K/AU

L5 0 S EXPRESS AND IGG FC AND COLONOCYTES AND KOBAYASHI, K/AU

L6 1 S L2 AND I-FCBS

=>

(FILE 'HOME' ENTERED AT 11:10:53 ON 25 AUG 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 11:13:12 ON 25 AUG 2003

SEA COLONOCYTE? AND IGA

4 FILE BIOSIS
4 FILE BIOTECHNO
1 FILE CAPLUS
4 FILE EMBASE
3 FILE ESBIODBASE
4 FILE IFIPAT
4 FILE MEDLINE
2 FILE PASCAL
1 FILE PROMT
4 FILE SCISEARCH
13 FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX

L1 QUE COLONOCYTE? AND IGA

FILE 'USPATFULL, BIOSIS, BIOTECHNO, EMBASE, IFIPAT, MEDLINE, SCISEARCH, ESBIODBASE, PASCAL, CAPLUS, PROMT, WPIDS' ENTERED AT 11:15:43 ON 25 AUG 2003

L2 45 S COLONOCYTE? AND IGA
L3 23 DUP REM L2 (22 DUPLICATES REMOVED)
L4 1 S L3 AND UC 11

WEST**End of Result Set**

Generate Collection

Print

L2: Entry 4 of 4

File: USPT

Jun 1, 1999

DOCUMENT-IDENTIFIER: US 5908825 A

** See image for Certificate of Correction **

TITLE: Dosage composition for nasal delivery and method of use of the same

Brief Summary Text (28):

(3) The regional effect of ZOT appears to be related to the distribution of its receptor within the intestine, i.e., the receptor is expressed only by mature cells on the tip of the villi in the jejunum and ileum. It is not present on the surface of colonocytes (Fiore et al, Gastroenterology, 110:A323 (1996)). Heretofore, it was not known whether the ZOT receptor was expressed on the surface of nasal mucosa.

Drawing Description Text (4):

FIG. 3 shows the anti-Ova secretory IgA antibodies in the nasal wash of mice treated with Ova alone (open bars), LT-R72+Ova (hatched bars), and ZOT+Ova (shaded bars).

Detailed Description Text (18):

Examples of immunoglobulins which can be employed in the present invention include polyvalent IgG or specific IgG, IgA and IgM, e.g., anti-tetanus antibodies.

Detailed Description Text (78):

ZOT and LT-R72 were also found to induce a mucosal immunoresponse, as determined by the elevated secretory IgA titer detected in the ELISA assay of the nasal washes of mice treated with either ZOT+Ova or LT-R72+Ova (see FIG. 3).

CLAIMS:

11. The nasal dosage composition of claim 8, wherein said globulin is an immunoglobulin selected from the group consisting of polyvalent IgG, and specific IgG, IgA or IgM.

26. The method of claim 23, wherein said globulin is an immunoglobulin selected from the group consisting of polyvalent IgG, and specific IgG, IgA or IgM.